Sector ratings Perspective Therapeutics, Inc.

Stocks

Real-time Estimate Cboe BZX Other stock markets 04:32:04 04/08/26 am AEST			5-day change	1st Jan Change
2.945 ^USD	+1.20%		+4.79%	+7.45%

28/07	Perspective Therapeutics' Neuroendocrine Tumor Therapy Receives EU Orphan Drug Designation	MT
18/07	Perspective Therapeutics Data On 212Pb VMT-a-NET Accepted For Oral Presentation At ESMO Congress 2026	CI

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Capi.($)	Investor	ESG MSCI	Fundamentals	Global Valuation
PERSPECTIVE THERAPEUTICS, INC.	332M	-	BBB	-	-
LONZA GROUP AG	48.53B		AAA
REVOLUTION MEDICINES, INC.	39.87B	-	B	-	-
IQVIA HOLDINGS INC.	38.68B		AAA
BEONE MEDICINES AG	35.13B		-
CELLTRION, INC.	29.79B		A
MEDPACE HOLDINGS, INC.	16.11B		BBB
ASCENDIS PHARMA A/S	16.08B	-	-	-	-
EUROFINS SCIENTIFIC SE	13.61B		AA
ICON PUBLIC LIMITED COMPANY	12.62B		AAA
BIO-TECHNE CORPORATION	11.23B		AA
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	11.2B		AA
ABIVAX	10.54B	-	BBB	-	-
APOGEE THERAPEUTICS, INC.	10.07B	-	B	-	-
PHARMARON BEIJING CO., LTD.	9.09B		AA
PROTAGONIST THERAPEUTICS, INC.	8.79B		BB		-
IONIS PHARMACEUTICALS, INC.	8.6B	-	A	-	-
PRAXIS PRECISION MEDICINES, INC.	8.58B	-	B	-	-
QIAGEN N.V.	8.56B		AAA
KYMERA THERAPEUTICS, INC.	8.51B	-	BBB	-	-
Average	17.3B		A
Weighted average by Cap.			A